Prediction of KIT Mutation in Gastrointestinal Stromal Tumors by the Immunoprofile of the Tumor Cells  by Chou, Chu-Chung et al.
J Formos Med Assoc | 2010 • Vol 109 • No 1 25
ORIGINAL ARTICLE
Gastrointestinal stromal tumors (GIST) is the
most common mesenchymal tumors of the gas-
trointestinal tract, and is resistant to conventional
chemotherapy and radiotherapy. The median sur-
vival for unresectable or metastatic GIST before the
emergence of targeted therapy was 9–20 months.1,2
Imatinib mesylate as a targeted therapeutic agent
has changed the survival of GIST patients drama-
tically.3,4 Furthermore, recent data have shown
that the responsiveness to imatinib is affected 
by KIT mutation. For example, Heinrich et al
showed that the partial response rate to imatinib
treatment of GIST with KIT mutation is signi-
ficantly better than those without mutation.5
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Background/Purpose: Human KIT protooncogene is the cellular homolog of v-kit from the Hardy–
Zuckerman 4 feline sarcoma virus, and encodes a 145-kDa type III tyrosine kinase growth factor receptor
that is often mutated in gastrointestinal stromal tumors (GIST). Standardized mutation analysis is not
available in many countries; therefore, we aimed to determine if the presence of KIT mutation in GIST can
be predicted by the immunoprofile of the tumor cells.
Methods: One hundred and forty-nine GIST were subjected to mutation analysis for KIT and immunohis-
tochemical analysis for the expression of CD117, CD34, α-smooth muscle actin (SMA), and S100 protein.
Mutation and immunohistochemistry data were correlated.
Results: KIT mutation rates were higher in certain immunoprofile subsets of GIST than in GIST in general.
Compared with the overall mutation rate of KIT (70%), all GIST with CD117+ and S100+ had > 80% prob-
ability of harboring mutated KIT, and the subset with additional CD34+ and SMA– had a mutation rate of
88%. The overall KIT mutation rate in CD117– GIST was 31%. However, the probability of KIT mutation
in CD117– GIST with CD34+SMA+S100–, CD34–SMA–S100+, and CD34+SMA–S100+ was 100%, 100%, and
67%, respectively. Compared with the overall mutation rate (8.7%) of exon 9, GISTs with CD34+SMA+
had ≥ 20% probability of harboring an exon 9 mutation, and all GISTs in the small intestine had a proba-
bility of 19%.
Conclusion: When mutation analysis is not available, immunoprofiles based on CD117, CD34, SMA, and
S100 can be used to predict the presence of KIT mutation, but it is less useful for the prediction of exon 9
mutation in GISTs. [J Formos Med Assoc 2010;109(1):25–31]
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Debiec-Rychter et al found that patients whose
GIST harbor KIT exon 9 mutations might need
high-dose imatinib treatment.6
Most KIT mutations identified in GIST are pres-
ent in exons 9 and 11, both of which affect the
ATP-binding site of the KIT tyrosine kinase. Al-
though GIST with mutated KIT respond to ima-
tinib treatment, KIT mutation is not present in
all GISTs. In fact, the frequency of KIT mutation
in GIST has varied between studies. In a large se-
ries that analyzed more than 100 GIST, we noted
that the KIT mutation rate was 79% in China,7
70% in Taiwan,8 64% in Sweden,9 59% in Spain,10
and 51–93% in the United States.5,11–13 Among
studies that have analyzed small GIST, we also
noted a wide range of KIT mutation frequencies:
Corless et al14 reported an 85% mutation rate in
GIST < 1 cm, Agaimy et al15 found a 46% muta-
tion rate in GIST tumorlets, and Andersson et al9
reported only a 33% mutation rate in GIST <1 cm.
For KIT mutations that are located specifically in
exon 9, we have reported that they are found
more frequently in GISTs of the small intestine.8
As a result of the association between the KIT
exon 9 mutation and relatively poor response to
imatinib treatment,6 GIST of the small bowel
might have a greater need of imatinib dose es-
calation. It is, therefore, important for clinicians
to know whether exon 9 mutation occurs in the
tumors of their GIST patients.
Although it is important to know if mutated
KIT is present in a given GIST when the patient is
considered for targeted therapy, mutation analy-
sis of KIT, a straightforward method that has been
used often for research purposes, is not provided
currently by most clinical laboratories. One of
the main obstacles is that mutation tests, like any
newly developed clinical assay, need a series of
validation procedures before clinical use.16 In
short, analytic accuracy (A), clinical validity (C),
clinical utility (C), and ethical, legal, and social
implications (E) constitute the ACCE model for
assessment of emerging genetic tests. The ACCE
review includes a long series of questions for the
validation of new assays. Only when the mutation
test is validated in a given laboratory can it be 
applied to patients. Therefore, a surrogate marker
is needed to provide the information about KIT
mutation before mutation analysis becomes a
standard assay. Our working hypothesis is that
KIT mutation might affect the expression of 
cellular proteins and therefore, can be predicted
by the immunoprofiles of GIST cells.
Materials and Methods
Patient series and diagnostic criteria
One hundred and forty-nine patients who were
diagnosed with GIST between 1994 and 2005 in
Mackay Memorial Hospital, Taiwan were in-
cluded. This study was approved by the Insti-
tutional Review Board of Mackay Memorial
Hospital. The diagnostic criteria of GIST have
been described in our previous report.8 In brief,
GIST have specific morphological features (spin-
dled, epithelioid, or mixed tumor cells) plus 
either CD117-immunopositivity or mutated KIT
or platelet-derived growth factor receptor alpha
(PDGFRA). With the specific morphological fea-
tures, the KIT or PDGFRA mutant tumors were
classified as GIST regardless of immunohisto-
chemical results.
DNA extraction, polymerase chain reaction
(PCR) and DNA sequencing
DNA was isolated from formalin-fixed paraffin-
embedded tumors as previously described.17
Four pairs of oligonucleotide primers were used
to amplify exons 9, 11, 13, and 17 of KIT by PCR
as previously described.18 The PCR products
were sequenced using the ABI PRISM BigDye
Terminator v3.1 Cycle Sequencing Kit and 3730
DNA Analyzer (Applied Biosystems, Foster City,
CA, USA).
Immunohistochemistry
For immunohistochemical staining, 5-μm re-
presentative sections of the specimens were 
deparaffinized, rehydrated, and probed with an-
tibodies against CD117 (1:50 dilution); CD34
(1:50); S100 protein (1:1500); and α-smooth
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muscle actin (SMA) (1:100; Dako, Carpinteria,.
CA, USA). Immunoreactivity was detected accord-
ing to the manufacturer’s instructions (Ventana
Medical Systems, Tucson, AZ, USA), using a 
mix of diaminobenzidine and hydrogen perox-
ide as the chromogen. Positive immunostaining
was defined as ≥ 15% of the tumor cells being
stained.
Statistical analysis
Sensitivity was the number of mutants that were
identified correctly by the presence of certain 
immunoprofiles, whereas specificity was the 
proportion of KIT wild-type that was identified
correctly by the absence of certain immunopro-
files. For example, if seven of eight tumors with
CD117+CD34+SMA–S100– were mutants, and 98
of 141 tumors without this specific immunophe-
notype were mutants, then the sensitivity of pre-
dicting KIT mutation by this immunophenotype
was 6% [7/(7 + 98)], whereas, the specificity was
97% [141 − 98/(8 − 7) + (141 − 98)]. Data were an-
alyzed by χ2 test and Fisher exact test, where ap-
propriate. Statistical data were obtained using
SPSS version 10.0 (SPSS Inc., Chicago, IL, USA).
Results
Immunoprofiles associated with the presence
of KIT mutation in GIST
Among the 149 GIST analyzed in this study, 
89% of tumors were CD117+, 73% were CD34+,
22% were SMA+, and 22% were S100+ (Table 1).
Of these, 105 GIST had KIT mutations. More
specifically, the KIT mutation rate was approxi-
mately 75% in CD117+, 31% in CD117–, 72% in
CD34+, 68% in CD34–, 67% in SMA+, 72% in
SMA–, 79% in S100+, and 68% in S100– GISTs.
There was no sex difference (55% male and
45% female) among the 105 mutated tumors
(Table 2). The patients were 60.5 ± 14.9 years 
of age. Approximately 46.7% occurred in the
stomach, 41.0% in the small intestine, 7.6% in
the colorectum, and 4.8% outside the gastroin-
testinal tract. Spindle, epithelioid, and mixed cell
types accounted for 83%, 7%, and 10% of the 
tumors, respectively.
Table 3 summarizes the probability of KIT
mutation in the CD117+ or CD117– GIST. For
CD117+ GIST, the probability of harboring mu-
tated KIT was 80–88%, when tumors were also
positive for S100. The specificity of predicting
KIT mutation was high (> 87%) in CD117+ GIST,
except for the subset that was associated with
CD34+SMA–S100–. Therefore, immunohistochem-
ical analysis of CD34, SMA, and S100 in CD117+
GISTs can help to predict the presence of KIT
mutations.
Five of 16 (31%) CD117– GIST had KIT muta-
tions (Table 1). Every CD117– GIST associated
with CD34+SMA+S100– or CD34–SMA–S100+ con-
tained KIT mutations (Table 3). The probability
of KIT mutation in CD117– GIST with CD34+
SMA–S100+ was 67%. The specificity of predict-
ing KIT mutation in CD117– GIST was high
(> 90%), except for those with CD34+SMA–S100–.
Therefore, certain immunoprofiles of CD34,
SMA, and S100 can be used to predict the pres-
ence of KIT mutation in CD117– GIST.
Prediction of KIT mutation in GIST
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Table 1. KIT mutation versus immunoprofiles in gastrointestinal stromal tumors*
SMA–S100– SMA+S100– SMA–S100+ SMA+S100+ Total
CD117+CD34+ 54/70 (77.14) 5/9 (55.56) 7/8 (87.50) 8/10 (80.00) 74/97 (76.29)
CD117+CD34– 10/14 (71.43) 8/12 (66.67) 8/10 (80.00) 0/0 26/36 (72.22)
CD117–CD34+ 1/8 (12.50) 1/1 (100.00) 2/3 (66.67) 0/0 4/12 (33.33)
CD117–CD34– 0/2 (0.00) 0/0 1/1 (100.00) 0/1 (0.00) 1/4 (25.00)
Total 65/94 (69.15) 14/22 (63.64) 18/22 (81.82) 8/11 (72.73) 105/149 (70.47)
*Data presented as number of KIT mutant/number of gastrointestinal stroma tumors in a given immunoprofile (%). SMA =a-smooth
muscle actin.
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Table 2. Demographic summary of 105 gastro-
intestinal stromal tumors with KIT mutation
No. Age Sex Tumor site Kit mutation
1 19.13 F Small intestine Exon 11
2 27.59 M Small intestine Exon 11
3 28.69 F Stomach Exon 11
4 28.99 M Small intestine Exon 11
5 29.23 F Small intestine Exon 9
6 37.26 F Colorectum Exon 11
7 38.07 F Stomach Exon 11
8 40.69 F Stomach Exon 11
9 40.75 M Small intestine Exon 11
10 40.84 M Small intestine Exon 11
11 41.68 M Small intestine Exon 11
12 41.68 M Small intestine Exon 11
13 43.15 M Small intestine Exon 11
14 44.09 M Small intestine Exon 11
15 44.70 F Small intestine Exon 11
16 44.84 M Small intestine Exon 11
17 45.52 F Stomach Exon 11
18 45.62 M Colorectum Exon 11
19 45.86 M Small intestine Exon 9
20 45.91 F Small intestine Exon 11
21 46.55 F Small intestine Exon 11
22 47.19 F Stomach Exon 11
23 47.43 M Stomach Exon 11
24 47.49 F Small intestine Exon 9
25 47.57 F Small intestine Exon 9
26 48.35 F Stomach Exon 11
27 48.69 M Outside the Exon 11
GI tract
28 49.46 M Stomach Exon 11
29 50.90 M Small intestine Exon 11
30 50.90 M Small intestine Exon 11
31 50.90 M Small intestine Exon 11
32 51.10 F Stomach Exon 11
33 51.10 F Stomach Exon 11
34 52.19 M Small intestine Exon 9
35 52.21 M Colorectum Exon 11
36 52.33 M Stomach Exon 11
37 52.57 F Colorectum Exon 11
38 53.71 F Small intestine Exon 11
39 54.64 M Small intestine Exon 11
40 55.35 M Colorectum Exon 11
41 55.67 M Stomach Exon 11
42 56.45 F Small intestine Exon 9
43 56.64 F Outside the Exon 11
GI tract
44 57.30 M Stomach Exon 11
45 58.19 M Outside the Exon 11
GI tract
46 58.94 M Colorectum Exon 9
47 59.55 M Stomach Exon 11
48 59.90 F Stomach Exon 11
49 60.80 M Small intestine Exon 11
50 61.55 M Small intestine Exon 11
51 62.08 M Small intestine Exon 11
52 62.32 F Stomach Exon 11
53 62.78 M Stomach Exon 11
54 63.38 M Small intestine Exon 11
55 64.07 F Small intestine Exon 11
56 64.31 F Small intestine Exon 9
57 64.94 M Small intestine Exon 9
58 64.95 M Outside the Exon 11
GI tract
59 65.14 F Small intestine Exon 11
60 65.35 F Small intestine Exon 9
61 65.55 M Stomach Exon 11
62 65.56 F Stomach Exon 11
63 66.21 M Stomach Exon 11
64 66.82 F Stomach Exon 11
65 67.03 F Stomach Exon 11
66 67.17 M Stomach Exon 11
67 67.64 F Stomach Exon 11
68 68.12 M Small intestine Exon 9
69 68.35 F Stomach Exon 11
70 68.73 F Stomach Exon 11
71 70.03 M Stomach Exon 11
72 70.25 M Colorectum Exon 11
73 70.29 M Stomach Exon 11
74 70.36 F Small intestine Exon 11
75 70.65 M Small intestine Exon 11
76 70.80 F Stomach Exon 11
77 71.09 M Small intestine Exon 11
78 71.54 M Stomach Exon 11
79 71.78 F Stomach Exon 11
80 71.81 M Small intestine Exon 11
81 72.11 M Small intestine Exon 11
82 72.21 M Colorectum Exon 11
83 72.82 M Stomach Exon 11
84 73.10 F Stomach Exon 9
85 73.76 M Stomach Exon 11
86 73.88 M Stomach Exon 11
87 74.05 M Stomach Exon 11
88 74.29 F Stomach Exon 11
89 74.32 M Stomach Exon 11
90 74.83 F Stomach Exon 11
91 75.55 M Small intestine Exon 9
92 76.44 F Stomach Exon 11
(Contd)
Immunoprofiles associated with KIT 
exon 9 mutation in GISTs
KIT exon 9 mutation was detected in 13 of 
149 (8.7%) tumors (Table 4). Of these, nine mu-
tants occurred in tumors associated with
SMA–S100–. To predict KIT exon 9 mutation,
CD34+ was not a better immunohistochemical
marker than SMA+, because exon 9 mutation 
rate in CD34+ GISTs was 9.2% as opposed to
12% in SMA+ GISTs. When SMA+ GIST were 
also positive for CD34, the probability of har-
boring exon 9 mutation increased to ≥ 20%
(Table 4).
When our analysis was limited to small-
bowel tumors, 19% (11/58) of GIST had exon 9
mutations (Table 5). Exon 9 mutation rate 
increased to 26% when the small-bowel GIST
were CD117+CD34+, 32% when tumors were
SMA–S100–, and 50% when the immunoprofile
was CD117+CD34+SMA–S100–.
Discussion
As a target agent, imatinib shows a better effect
on GISTs that harbor KIT mutations than on
those with wild-type KIT,5 which indicates the
importance of determining whether a given GIST
has a KIT mutation when imatinib treatment is
considered. However, KIT mutation is not pres-
ent routinely in all GIST because the mutation
rate can be as low as 50–60%.10,13 It is, therefore,
necessary to perform mutation tests for every
GIST. However, not many laboratories provide a
clinical service for mutation analysis, particularly
when quality assessment and control are deemed
prerequisites for clinical tests. To find a substi-
tute for KIT mutation analysis, we showed in this
study that immunoprofiles can be used to pre-
dict the presence of KIT mutation in GISTs, with
relatively good specificity.
In relation to the need of predicting exon 9
mutation because of its association with ima-
tinib dose escalation in GIST patients,6 our data
were discouraging. We showed that exon 9 muta-
tion is difficult to predict by immunoprofile, ex-
cept the rare subset of CD117–SMA+S100– GIST,
which has a mutation rate of 100%. However,
SMA+ was associated with a slightly increased
exon 9 mutation rate (12%) compared with the
overall rate (8%). When tumors were in the
small bowel, the subset of GISTs that exhibited
CD117+CD34+SMA–S100– might have had a 50%
chance of containing an exon 9 mutation.
An ever-increasing number of kinase inhib-
itors are emerging for targeted anticancer treat-
ment, therefore, molecular tests are needed for
diagnostic and therapeutic purposes. However,
the unavoidable dilemma in the era of molecular
medicine is that it takes time to transform re-
search methods into clinical tests, while treat-
ment decisions cannot wait. In this regard, the
present study illustrates that immunoprofiles
based on four immunohistochemical markers can
be a surrogate tool for mutational analysis, be-
cause immunohistochemistry is a simple method
with well-established quality control and assess-
ment, whereas mutation analysis is an emerging
and still empirical test from the clinical point of
view. Nevertheless, it should be stressed that
completely replacing mutation analysis with 
immunohistochemistry is out of the question
and unnecessary.
Prediction of KIT mutation in GIST
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Table 2. Contd
No. Age Sex Tumor site Kit mutation
93 77.16 F Outside the Exon 11
GI tract
94 79.14 F Stomach Exon 11
95 79.38 F Small intestine Exon 11
96 79.51 F Stomach Exon 11
97 79.95 F Stomach Exon 11
98 80.99 M Small intestine Exon 11
99 81.27 M Stomach Exon 11
100 82.54 F Stomach Exon 11
101 82.93 M Stomach Exon 11
102 84.13 M Stomach Exon 11
103 85.35 M Stomach Exon 11
104 87.25 F Stomach Exon 11
105 91.53 F Small intestine Exon 11
F = female; M = male; GI = gastrointestinal.
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Table 3. Sensitivity and specificity of immunoprofiles in predicting KIT mutation in gastrointestinal stromal
tumors
Immunoprofiles* Predicting KIT mutation†
CD117 CD34 SMA S100 Probability of a positive test Sensitivity Specificity
+ + – + 88 7 97
+ – – + 80 8 94
+ + + + 80 8 94
+ + – – 77 54 52
+ – – – 71 10 88
+ – + – 67 8 88
+ + + – 56 5 88
– + + – 100 20 100
– + – + 67 40 91
– + – – 13 20 36
– – – + 100 20 100
*Other immunoprofiles not listed here are either free of KIT mutation or nonexistent in this study; †data presented as %. SMA =
a-smooth muscle actin.
Table 4. KIT exon 9 mutation versus immunoprofiles in gastrointestinal stromal tumors*
SMA−S100− SMA+S100− SMA−S100+ SMA+S100+ Total
CD117+CD34+ 7/70† (10.00) 0/9 (0) 0/8 (0) 2/10 (20.00) 9/97 (9.28)
5/10‡ (50.00) 0/3 (0) 0/5 (0) 2/9 (22.22) 2/27 (7.41)
CD117+CD34− 2/14 (14.29) 1/12 (8.33) 0/10 (0) 0/0 3/36 (8.33)
2/11 (18.18) 1/10 (10.00) 0/8 (0) 0/0 3/29 (10.34)
CD117−CD34+ 0/8 (0) 1/1 (100) 0/3 (0) 0/0 1/12 (8.33)
0/1 (0) 1/1 (100) 0/0 0/0 1/2 (50.00)
CD117−CD34− 0/2 (0) 0/0 0/1 (0) 0/1 (0) 0/4 (0)
0/0 0/0 0/0 0/0 0/0
Total 9/94 (9.57) 2/22 (9.09) 0/22 (0) 2/11 (18.18) 13/149 (8.72)
7/22 (31.82) 2/14 (14.29) 0/13 (0) 2/9 (22.22) 11/58 (18.97)
*Data presented as number of exon 9 mutation/number of gastrointestinal stromal tumors in a given immunoprofile (%); †first row
represent gastrointestinal stromal tumors at any site; ‡second row represent gastrointestinal stromal tumors in the small intestine.
SMA = a-smooth muscle actin.
Table 5. Prediction of exon 9 mutation by various immunoprofiles in gastrointestinal stromal tumors
Immunoprofiles* Probability of exon 9 mutation by a positive test†
CD117 CD34 SMA S100 GIST at any site GIST in the small bowel
− + + − 100 100
+ + − − 10 50
+ + + + 20 22
+ − − − 14 18
+ − + − 8 10
*Other immunoprofiles not listed here are either free of exon 9 mutation or nonexistent in this study; †data presented as %. SMA =
a-smooth muscle actin; GIST = gastrointestinal stromal tumor.
In conclusion, we recommend that CD117,
CD34, SMA and S100 should be employed for
immunohistochemical analysis of every case of
GIST when mutation analysis is not available.
The combination of these four markers is valu-
able for the prediction of KIT mutation in gen-
eral and, to a lesser degree, the exon 9 mutation
in GIST.
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